Cargando…
Systemic effects of intratympanic dexamethasone therapy
OBJECTIVE: The study aimed to assess the possible systemic effects of intratympanic dexamethasone (IT-Dex) on the hypothalamic–pituitary–adrenal (HPA) axis, inflammation, and bone metabolism. DESIGN: A prospective cohort study including 30 adult patients of a tertiary referral ENT clinic treated wit...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134486/ https://www.ncbi.nlm.nih.gov/pubmed/25055818 http://dx.doi.org/10.1530/EC-14-0076 |
_version_ | 1782330876724510720 |
---|---|
author | Novoa, Eva Gärtner, Marcel Henzen, Christoph |
author_facet | Novoa, Eva Gärtner, Marcel Henzen, Christoph |
author_sort | Novoa, Eva |
collection | PubMed |
description | OBJECTIVE: The study aimed to assess the possible systemic effects of intratympanic dexamethasone (IT-Dex) on the hypothalamic–pituitary–adrenal (HPA) axis, inflammation, and bone metabolism. DESIGN: A prospective cohort study including 30 adult patients of a tertiary referral ENT clinic treated with 9.6 mg IT-Dex over a period of 10 days was carried out. METHODS: Effects on plasma and salivary cortisol concentrations (basal and after low-dose (1 μg) ACTH stimulation), peripheral white blood cell count, and biomarkers for bone turnover were measured before (day 0) and after IT-Dex (day 16). Additional measurements for bone turnover were performed 5 months after therapy. Clinical information and medication with possible dexamethasone interaction were recorded. RESULTS: IT-Dex was well tolerated, and no effect was detected on the HPA axis (stimulated plasma and salivary cortisol concentration on day 0: 758±184 and 44.5±22.0 nmol/l; day 16: 718±154 and 39.8±12.4 nmol/l; P=0.58 and 0.24 respectively). Concentrations of osteocalcin (OC) and bone-specific alkaline phosphatase (BSAP) did not differ after dexamethasone (OC on days 0 and 16 respectively: 24.1±10.5 and 23.6±8.8 μg/l; BSAP on day 0, 16, and after 5 months respectively: 11.5±4.2, 10.3±3.4, and 12.6±5.06 μg/l); similarly, there was no difference in the peripheral white blood cell count (5.7×10(12)/l and 6.1×10(12)/l on days 0 and 16 respectively). CONCLUSIONS: IT-Dex therapy did not interfere with endogenous cortisol secretion or bone metabolism. |
format | Online Article Text |
id | pubmed-4134486 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-41344862014-08-26 Systemic effects of intratympanic dexamethasone therapy Novoa, Eva Gärtner, Marcel Henzen, Christoph Endocr Connect Research OBJECTIVE: The study aimed to assess the possible systemic effects of intratympanic dexamethasone (IT-Dex) on the hypothalamic–pituitary–adrenal (HPA) axis, inflammation, and bone metabolism. DESIGN: A prospective cohort study including 30 adult patients of a tertiary referral ENT clinic treated with 9.6 mg IT-Dex over a period of 10 days was carried out. METHODS: Effects on plasma and salivary cortisol concentrations (basal and after low-dose (1 μg) ACTH stimulation), peripheral white blood cell count, and biomarkers for bone turnover were measured before (day 0) and after IT-Dex (day 16). Additional measurements for bone turnover were performed 5 months after therapy. Clinical information and medication with possible dexamethasone interaction were recorded. RESULTS: IT-Dex was well tolerated, and no effect was detected on the HPA axis (stimulated plasma and salivary cortisol concentration on day 0: 758±184 and 44.5±22.0 nmol/l; day 16: 718±154 and 39.8±12.4 nmol/l; P=0.58 and 0.24 respectively). Concentrations of osteocalcin (OC) and bone-specific alkaline phosphatase (BSAP) did not differ after dexamethasone (OC on days 0 and 16 respectively: 24.1±10.5 and 23.6±8.8 μg/l; BSAP on day 0, 16, and after 5 months respectively: 11.5±4.2, 10.3±3.4, and 12.6±5.06 μg/l); similarly, there was no difference in the peripheral white blood cell count (5.7×10(12)/l and 6.1×10(12)/l on days 0 and 16 respectively). CONCLUSIONS: IT-Dex therapy did not interfere with endogenous cortisol secretion or bone metabolism. Bioscientifica Ltd 2014-08-14 /pmc/articles/PMC4134486/ /pubmed/25055818 http://dx.doi.org/10.1530/EC-14-0076 Text en © 2014 The authors http://creativecommons.org/licenses/by/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/deed.en_GB) |
spellingShingle | Research Novoa, Eva Gärtner, Marcel Henzen, Christoph Systemic effects of intratympanic dexamethasone therapy |
title | Systemic effects of intratympanic dexamethasone therapy |
title_full | Systemic effects of intratympanic dexamethasone therapy |
title_fullStr | Systemic effects of intratympanic dexamethasone therapy |
title_full_unstemmed | Systemic effects of intratympanic dexamethasone therapy |
title_short | Systemic effects of intratympanic dexamethasone therapy |
title_sort | systemic effects of intratympanic dexamethasone therapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134486/ https://www.ncbi.nlm.nih.gov/pubmed/25055818 http://dx.doi.org/10.1530/EC-14-0076 |
work_keys_str_mv | AT novoaeva systemiceffectsofintratympanicdexamethasonetherapy AT gartnermarcel systemiceffectsofintratympanicdexamethasonetherapy AT henzenchristoph systemiceffectsofintratympanicdexamethasonetherapy |